Upsher-Smith Laboratories LLC, a United States-based pharmaceutical company, has signed a collaboration agreement with United States-based AmbioPharm Inc to produce and market Corticotropin Injection in the United States, it was reported on Friday.
According to the terms of the contract, Upsher-Smith is submitting the New Drug Application (NDA) for Corticotropin Injection to the United States Food and Drug Administration (FDA) and will market and distribute the product under its own label in the United States, after US FDA approval.
AmbioPharm is to produce the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organisation is to provide Upsher-Smith with the finished product for sale in the United States.
Financial terms of the deal were not revealed.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval